Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction

Blood

Volumn 113, Issue 8, 2009, Pages 1681-1688

  Fonseca, Catia ^a,b   Soiffer, Robert ^a,b   Ho, Vincent ^a,b   Vanneman, Matthew ^a,b   Jinushi, Masahisa ^a,b   Ritz, Jerome ^a,b   Neuberg, Donna ^b   Stone, Richard ^a,b   DeAngelo, Dan ^a,b   Dranoff, Glenn ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HLA A ANTIGEN; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 CHAIN RELATED PROTEIN A; NUCLEIC ACID; PROTEIN; PROTEIN DERIVATIVE; PROTEIN DISULFIDE ISOMERASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CELL BASED GENE THERAPY; CELL METABOLISM; CELL MIGRATION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MELANOMA; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SOLID TUMOR; STRESS; TUMOR CELL; TUMOR IMMUNITY;

EID: 61849145128     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-114157     Document Type: Article

References (64)

1. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11-22.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296.
3. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
4. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory Tcell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538-18543.
5. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
6. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059.
7. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117:1195-1203.
8. Dranoff G, Jaffee E, LazenbyA, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
9. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965.
10. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res. 2000;60:3239-3246.
11. Gillessen S, Naumov YN, Nieuwenhuis EE, et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA. 2003;100: 8874-8879.
12. Reilly R, Machiels J-P, Emens L, et al. The collaboration of both humoral and cellular HER-2/ neu-targeted immune responses is required for the complete eradication of HER-2/neu-express-ing tumors. Cancer Res. 2001;61:880-883.
13. Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv Immunol. 2006;90:337-360.
14. Korman A, Peggs K, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:293-335.
15. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7:445-450.
16. Doyle AM, Mullen AC, Villarino AV, et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med. 2001;194:893-902.
17. Salomon B, Bluestone JA. Complexities of CD28/ B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
18. van Elsas A, Hurwitz A, Allison J. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355-366.
19. Hurwitz A, Yu T, Leach D, Allison J. CTLA-4 blockade synergizes with tumor-derived granulo-cyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. 1998;95:10067-10071.
20. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60:2444-2448.
21. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712-4717.
22. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186-1190.
23. Gonzalez S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Micro-biol Immunol. 2006;298:121-138.
24. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006;103:9190-9195.
25. Schmollinger JC, Vonderheide RH, Hoar KM, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003;100: 3398-3403.
26. Hodi FS, Schmollinger JC, Soiffer RJ, et al. ATP6S1 elicits potent humoral responses associated with immune mediated tumor destruction. Proc Natl Acad Sci U S A. 2002;99:6919-6924.
27. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. 1998;95: 13141-13146.
28. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21:3343-3350.
29. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colonystimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21:624-630.
30. + T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
31. Manis J, Tian M, Alt F. Mechanism and control of class-switch recombination. Trends Immunol. 2002;23:31-39.
32. Itoh K, Yoshioka K, Akedo H, UehataM, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med. 1999;5:221-225.
33. Okamoto I, Kawano Y, Tsuiki H, et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene. 1999;18:1435-1446.
34. Barnhart BC, Simon MC. Taking aim at translation for tumor therapy. J Clin Invest. 2007;117:2385-2388.
35. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006;57:33-47.
36. Levine B. Cell biology: autophagy and cancer. Nature. 2007;446:745-747.
37. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006;13(suppl 1):S125-S135.
38. Goldstein JL, Brown MS. Regulation of the meva-lonate pathway. Nature. 1990;343:425-430.
39. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007;12: 108-113.
40. Gilboa E. The makings of a tumor rejection antigen. Immunity. 1999;11:263-270.
41. Scanlan MJ, Gordan JD, Williamson B, et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 1999;83:456-464.
42. Eberle J, Krasagakis K, Orfanos CE. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer. 1997;71:396-401.
43. Hartmann TB, Thiel D, Dummer R, Schadendorf D, Eichmuller S. SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol. 2004;150:252-258.
44. Freedman RB, Bulleid NJ, Hawkins HC, Paver JL. Role of protein disulphide-isomerase in the expression of native proteins. Biochem Soc Symp. 1989;55:167-192.
45. Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta. 2004;1699:35-44.
46. Ferrari DM, Soling HD. The protein disulphide-isomerase family: unravelling a string of folds. Biochem J. 1999;339:1-10.
47. Ellgaard L, Ruddock LW. The human protein dis-ulphide isomerase family: substrate interactions and functional properties. EMBO Rep. 2005;6:28-32.
48. Tager M, Kroning H, Thiel U,Ansorge S. Membrane-bound protein disulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Exp Hematol. 1997;25:601-607.
49. Turano C, Coppari S, Altieri F, Ferraro A. Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol. 2002;193:154-163.
50. Lahav J, Gofer-Dadosh N, Luboshitz J, Hess O, Shaklai M. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Lett. 2000; 475:89-92.
51. Teshima T, Mach N, Hill GR, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 2001;61:162-171.
52. Teshima T, Liu C, Lowler KP, Dranoff G, Ferrara JL. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allo-geneic bone marrow transplantation. Cancer Res. 2002;62:796-800.
53. Kaiser BK, Yim D, Chow IT, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007;447:482-486.
54. Diefenbach A, Raulet D. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002;188:9-21.
55. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J Clin Immunol. 2005;25: 534-540.
56. Goplen D, Wang J, Enger PO, et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006;66:9895-9902.
57. Gumireddy K, Sun F, Klein-Szanto AJ, et al. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci U S A. 2007;104: 6696-6701.
58. Berland R, Fernandez L, Kari E, et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity. 2006;25:429-440.
59. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25:417-428.
60. Fineschi S, Borghi MO, Riboldi P, et al. Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythema-tosus. Lupus. 2004;13:463-468.
61. Heegaard NH, Larsen MR, Muncrief T, Wiik A, Roepstorff P. Heterogeneous nuclear ribonucleo-proteins C1/C2 identified as autoantigens by biochemical and mass spectrometric methods. Arthritis Res. 2000;2:407-414.
62. Minota S, Nojima Y, Yamada A, Kanai Y, Winfield JB, Takaku F. Specificity of autoantibodies to his-tone H1 in SLE: relationship to DNA-binding domains. Autoimmunity. 1991;9:13-19.
63. Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8 mediated uptake of apoptotic cells by APCs links the pro- and anti-inflammatory activities of GM-CSF. J Clin Invest. 2007;117:1902-1913.
64. Dhodapkar KM, Dhodapkar MV. Recruiting dendritic cells to improve antibody therapy of cancer. Proc Natl Acad Sci U S A. 2005;102:6243-6244.